To compare rates of decline in patients with mild to moderate Alzheimer 's disease ( AD ) receiving CACE-Is to those not currently treated with CACE-Is ( NoCACE-I ) , included in the Doxycycline and Rifampicin for Alzheimer 's Disease study ( n = 406 ) .